Niraparib Shows Mixed Signals in Early Prostate Cancer Treatment

MedPage Today) — At the recent American Urological Association annual meeting, data on niraparib (Zejula) in treatment-naive, DNA damage repair (DDR)-deficient localized prostate cancer offered new insights — but also raised important questions…